Skip to main content

Table 3 Correlation between clinicopathological features and each intrinsic subtype in 55 patients with recurrence after surgery

From: Significance of intrinsic breast cancer subtypes on the long-term prognosis after neoadjuvant chemotherapy

Parameters Intrinsic subtype p-value
Luminal
(n = 23)
Luminal-HER2
(n = 3)
HER2-enriched
(n = 9)
TNBC
(n = 20)
Age at operation
 ≤ 56 13 (56.5%) 2 (66.7%) 5 (55.6%) 11 (55.0%)  
 > 56 10 (43.5%) 1 (33.3%) 4 (44.4%) 9 (45.0%) 0.985
Menopause
 Pre- 10 (43.5%) 2 (66.7%) 4 (44.4%) 8 (40.0%)  
 Post- 13 (56.5%) 1 (33.3%) 5 (55.6%) 12 (60.0%) 0.860
Tumor size (cm)
 ≤ 2 2 (8.7%) 0 (0.0%) 1 (11.1%) 2 (10.0%)  
 > 2 21 (91.3%) 3 (100.0%) 8 (88.9%) 18 (90.0%) 0.888
Lymph node status
 Negative 2 (8.7%) 1 (33.3%) 2 (22.2%) 5 (25.0%)  
 Positive 21 (91.3%) 2 (66.7%) 7 (77.8%) 15 (75.0%) 0.437
Nuclear grade
 1, 2 18 (78.3%) 3 (100.0%) 8 (88.9%) 16 (80.0%)  
 3 5 (21.7%) 0 (0.0%) 1 (11.1%) 4 (20.0%) 0.620
Ki67 (%)
 ≤ 14 11 (47.8%) 3 (100.0%) 4 (44.4%) 8 (40.0%)  
 > 14 12 (52.2%) 0 (0.0%) 5 (55.6%) 12 (60.0%) 0.175
Pathological response
 Non-pCR 17 (73.9%) 3 (100.0%) 5 (55.6%) 16 (80.0%)  
 pCR 6 (26.1%) 0 (0.0%) 4 (44.4%) 4 (20.0%) 0.306
Metastatic site
 Local/bone 16 (69.6%) 2 (66.7%) 5 (55.6%) 12 (60.0%)  
 Distant 7 (30.4%) 1 (33.3%) 4 (44.4%) 8 (40.0%) 0.866
Relapse-free survival (years)
 < 2 13 (56.5%) 1 (33.3%) 5 (55.6%) 16 (80.0%)  
 ≥ 2 10 (43.5%) 2 (66.7%) 4 (44.4%) 4 (20.0%) 0.220
  1. HER2 human epidermal growth factor receptor 2, TNBC triple-negative breast cancer, pCR pathological complete response